Related Experiment Video
Updated: Jul 5, 2025
Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
Published on: September 26, 2016
Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers
Huanrong Lan1, Bo Wu1, Ketao Jin2
1Department of Surgical Oncology, Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China.
Abstract:
Evidence demonstrated that bones, liver, and lungs are the most common metastasis sites in some human malignancies, especially in prostate and breast cancers. Bone is the third most frequent target for spreading tumor cells among these organs and tissues. Patients with bone-metastatic cancers face a grim prognosis characterized by short median survival time. Current treatments have proven insufficient, as they can only inhibit metastasis or tumor progression within the bone tissues rather than providing a curative solution. Gaining a more profound comprehension of the interplay between tumor cells and the bone microenvironment (BME) is of utmost importance in tackling this issue. This knowledge will pave the way for developing innovative diagnostic and therapeutic approaches. This review summarizes the mechanisms underlying bone metastasis and discusses the clinical aspects of this pathologic condition. Additionally, it highlights emerging therapeutic interventions aimed at enhancing the quality of life for patients affected by bone-metastatic cancers. By synthesizing current research, this review seeks to shed light on the complexities of bone metastasis and offer insights for future advancements in patient care.
Insights
Bone metastasis is a common and serious complication of cancer, particularly prostate and breast cancer. Understanding tumor cell interactions with the bone microenvironment (BME) is crucial for developing better treatments.
Area of Science:
- Oncology
- Cancer Biology
- Skeletal Biology
Background:
- Bone metastasis is a frequent complication in advanced cancers, notably prostate and breast cancer, significantly impacting patient prognosis.
- The bone microenvironment (BME) plays a critical role in supporting tumor cell survival and progression.
- Current treatments for bone metastasis offer limited efficacy, focusing on inhibition rather than cure.
Purpose of the Study:
- To review the mechanisms driving bone metastasis.
- To discuss the clinical implications of bone metastasis.
- To highlight novel therapeutic strategies for bone-metastatic cancers.
Main Methods:
- Literature review synthesizing current research on bone metastasis.
- Analysis of the interplay between tumor cells and the bone microenvironment.
- Examination of clinical aspects and emerging treatments.
Main Results:
- Bone metastasis is a complex process involving intricate interactions within the BME.
- Prognosis for patients with bone metastasis remains poor, with limited curative options.
- Emerging therapies show promise in managing bone metastasis and improving patient quality of life.
Conclusions:
- A deeper understanding of tumor-BME interactions is essential for advancing bone metastasis research.
- Innovative diagnostic and therapeutic strategies are needed to improve outcomes for patients with bone metastasis.
- This review provides insights into current challenges and future directions in managing bone metastasis.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...